Barclays lowered the firm’s price target on Avantor (AVTR) to $15 from $18 and keeps an Overweight rating on the shares following the Q1 report. The company core guidance cut was largely expected, but there has been a lot of negative feedback on not including potential tariffs in the outlook, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
- Avantor’s Hold Rating: Challenges in Bioprocess and Lab Consumables Amid Low Valuation
- Avantor downgraded to Hold from Buy at TD Cowen
- Avantor’s Hold Rating: Navigating Revenue Misses, Bioprocess Challenges, and Leadership Uncertainty
- Avantor’s Performance Challenges and Uncertain Outlook Lead to Hold Rating
- Avantor downgraded to Equal Weight from Overweight at Morgan Stanley